A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).

Yotsuyanagi, Hiroshi; Ohmagari, Norio; Doi, Yohei; Imamura, Takumi; Sonoyama, Takuhiro; Ichihashi, Genki; Sanaki, Takao; Tsuge, Yuko; Uehara, Takeki; Mukae, Hiroshi

Yotsuyanagi, Hiroshi; Ohmagari, Norio; Doi, Yohei; Imamura, Takumi; Sonoyama, Takuhiro; Ichihashi, Genki; Sanaki, Takao; Tsuge, Yuko; Uehara, Takeki; Mukae, Hiroshi.

Affiliation

Yotsuyanagi H; The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Doi Y; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Imamura T; Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan.
Sonoyama T; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Ichihashi G; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Sanaki T; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Tsuge Y; Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Uehara T; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Mukae H; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.

Medicine (Baltimore) ; 102(8): e33024, 2023 Feb 22.

Article in En | MEDLINE | ID: mdl-36827007

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Clinical_trials / Guideline Limits: Humans Language: En Journal: Medicine (Baltimore) Year: 2023 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google